Porton Pharma Solutions Ltd. (300363.SZ)
CNY 16.53
(-1.31%)
CNY 16.53
(-1.31%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 266.85 Million CNY | -86.69% |
| 2022 | 2 Billion CNY | 282.78% |
| 2021 | 523.91 Million CNY | 61.49% |
| 2020 | 324.41 Million CNY | 74.84% |
| 2019 | 185.55 Million CNY | 49.04% |
| 2018 | 124.49 Million CNY | 15.86% |
| 2017 | 107.44 Million CNY | -37.23% |
| 2016 | 171.18 Million CNY | 55.07% |
| 2015 | 110.39 Million CNY | -12.03% |
| 2014 | 125.48 Million CNY | 25.23% |
| 2013 | 100.2 Million CNY | 24.82% |
| 2012 | 80.27 Million CNY | 28.66% |
| 2011 | 62.39 Million CNY | 44.94% |
| 2010 | 43.04 Million CNY | 42.39% |
| 2009 | 30.23 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -75.16 Million CNY | 20.77% |
| 2024 Q3 | -36.39 Million CNY | 51.58% |
| 2024 Q1 | -94.87 Million CNY | 48.72% |
| 2023 Q4 | -184.99 Million CNY | -545.93% |
| 2023 Q1 | 304.09 Million CNY | -28.89% |
| 2023 Q3 | 41.48 Million CNY | -60.97% |
| 2023 Q2 | 106.28 Million CNY | -65.05% |
| 2023 FY | 266.85 Million CNY | -86.69% |
| 2022 Q2 | 830.43 Million CNY | 117.45% |
| 2022 FY | 2 Billion CNY | 282.78% |
| 2022 Q4 | 427.65 Million CNY | 17.02% |
| 2022 Q3 | 365.44 Million CNY | -55.99% |
| 2022 Q1 | 381.89 Million CNY | 133.99% |
| 2021 FY | 523.91 Million CNY | 61.49% |
| 2021 Q1 | 88.09 Million CNY | 3.14% |
| 2021 Q4 | 163.21 Million CNY | 11.69% |
| 2021 Q3 | 146.13 Million CNY | 15.54% |
| 2021 Q2 | 126.47 Million CNY | 43.58% |
| 2020 FY | 324.41 Million CNY | 74.84% |
| 2020 Q4 | 85.41 Million CNY | -20.96% |
| 2020 Q3 | 108.06 Million CNY | 30.54% |
| 2020 Q2 | 82.77 Million CNY | 71.87% |
| 2020 Q1 | 48.16 Million CNY | -3.34% |
| 2019 Q3 | 70.4 Million CNY | 44.28% |
| 2019 Q4 | 49.83 Million CNY | -29.23% |
| 2019 FY | 185.55 Million CNY | 49.04% |
| 2019 Q1 | 16.51 Million CNY | -38.49% |
| 2019 Q2 | 48.79 Million CNY | 195.56% |
| 2018 Q2 | 8.65 Million CNY | -60.77% |
| 2018 FY | 124.49 Million CNY | 15.86% |
| 2018 Q4 | 26.84 Million CNY | -59.9% |
| 2018 Q3 | 66.93 Million CNY | 673.37% |
| 2018 Q1 | 22.06 Million CNY | -39.47% |
| 2017 Q1 | 56.4 Million CNY | 12.87% |
| 2017 FY | 107.44 Million CNY | -37.23% |
| 2017 Q4 | 36.45 Million CNY | 220.18% |
| 2017 Q3 | 11.38 Million CNY | 254.9% |
| 2017 Q2 | 3.2 Million CNY | -94.31% |
| 2016 Q3 | 28.31 Million CNY | -40.14% |
| 2016 Q2 | 47.3 Million CNY | 3.73% |
| 2016 Q4 | 49.97 Million CNY | 76.48% |
| 2016 FY | 171.18 Million CNY | 55.07% |
| 2016 Q1 | 45.59 Million CNY | 70.5% |
| 2015 FY | 110.39 Million CNY | -12.03% |
| 2015 Q4 | 26.74 Million CNY | -5.18% |
| 2015 Q3 | 28.2 Million CNY | 16.51% |
| 2015 Q2 | 24.2 Million CNY | -22.51% |
| 2015 Q1 | 31.23 Million CNY | -46.79% |
| 2014 Q2 | 12.81 Million CNY | -56.72% |
| 2014 Q1 | 29.61 Million CNY | 638.11% |
| 2014 FY | 125.48 Million CNY | 25.23% |
| 2014 Q4 | 58.71 Million CNY | 141.21% |
| 2014 Q3 | 24.34 Million CNY | 89.9% |
| 2013 Q2 | 15.39 Million CNY | -61.25% |
| 2013 FY | 100.2 Million CNY | 24.82% |
| 2013 Q1 | 39.72 Million CNY | 0.0% |
| 2013 Q3 | 41.06 Million CNY | 166.78% |
| 2013 Q4 | 4.01 Million CNY | -90.23% |
| 2012 FY | 80.27 Million CNY | 28.66% |
| 2011 FY | 62.39 Million CNY | 44.94% |
| 2010 FY | 43.04 Million CNY | 42.39% |
| 2009 FY | 30.23 Million CNY | 0.0% |